PMID- 20840192
OWN - NLM
STAT- MEDLINE
DCOM- 20120524
LR  - 20120126
IS  - 1755-5922 (Electronic)
IS  - 1755-5914 (Linking)
VI  - 30
IP  - 1
DP  - 2012 Feb
TI  - Role of antiischemic agents in the management of non-ST elevation acute coronary 
      syndrome (NSTE-ACS).
PG  - e16-22
LID - 10.1111/j.1755-5922.2010.00225.x [doi]
AB  - Non-ST elevation acute coronary syndrome (NSTE-ACS) is the commonest acute 
      presentation of coronary artery disease (CAD). Mortality and morbidity of the 
      condition has improved substantially over the last few decades as a result of the 
      cumulative effect of multiple interventions acting via different mechanisms. 
      Despite a significant increase in the rate of coronary intervention, medical 
      therapy continues to retain a central role in the treatment of NSTE-ACS 
      particularly in frail patients where revascularization is inappropriate or when 
      it is incomplete. Several antiischemic agents have been used in the treatment of 
      the condition. Beta blockers are often the first-line choice with calcium channel 
      blockers and nitrates being used as an alternative when beta blockers are 
      contraindicated, or as an addition to achieve optimal symptom control. Newer 
      agents, such as nicorandil, ivabradine, and ranolazine have also been used in 
      refractory cases. Although most of these agents have been extensively studied in 
      large randomized controlled trials in patients with stable CAD or ST elevation 
      acute coronary syndrome (STE-ACS), the evidence supporting their use in NSTE-ACS 
      is less clear cut. In this article, we review various drugs available for 
      controlling ischemia and the latest evidence in support of their use in NSTE-ACS.
CI  - (c) 2010 Blackwell Publishing Ltd.
FAU - El-Kadri, Moutaz
AU  - El-Kadri M
AD  - Liverpool Heart and Chest Hospital NHS Foundation Trust, Thomas Drive, Liverpool, 
      UK. moutazkad@hotmail.com
FAU - Sharaf-Dabbagh, Hala
AU  - Sharaf-Dabbagh H
FAU - Ramsdale, David
AU  - Ramsdale D
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20100915
PL  - England
TA  - Cardiovasc Ther
JT  - Cardiovascular therapeutics
JID - 101319630
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Calcium Channel Blockers)
RN  - 0 (Cardiovascular Agents)
RN  - 0 (Vasodilator Agents)
SB  - IM
MH  - Acute Coronary Syndrome/*drug therapy/physiopathology
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Calcium Channel Blockers/therapeutic use
MH  - Cardiovascular Agents/*therapeutic use
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Myocardial Ischemia/*drug therapy/physiopathology
MH  - Treatment Outcome
MH  - Vasodilator Agents/therapeutic use
EDAT- 2010/09/16 06:00
MHDA- 2012/05/25 06:00
CRDT- 2010/09/16 06:00
PHST- 2010/09/16 06:00 [entrez]
PHST- 2010/09/16 06:00 [pubmed]
PHST- 2012/05/25 06:00 [medline]
AID - 10.1111/j.1755-5922.2010.00225.x [doi]
PST - ppublish
SO  - Cardiovasc Ther. 2012 Feb;30(1):e16-22. doi: 10.1111/j.1755-5922.2010.00225.x. 
      Epub 2010 Sep 15.